Department of Neurosurgery, The First Affiliated Hospital of Wannan Medical College, Wuhu City 241001, China.
Department of Neurosurgery, The Second Affiliated Hospital of Wannan Medical College, Wuhu City 41001, China.
Biosci Rep. 2018 Nov 20;38(6). doi: 10.1042/BSR20180646. Print 2018 Dec 21.
MiRNAs are important regulators of translation and have been described as biomarkers of a number of cardiovascular diseases, including stroke. The purpose of the study was to determine expression levels of serum miR-1297 in patients with aneurysmal subarachnoid hemorrhage (aSAH), and to assess whether miR-1297 was the prognostic indicator of aSAH. We treated 128 aSAH patients with endovascular coiling. The World Federation of Neurological Surgeons (WFNS) grades, Hunt-Hess grades, and modified Fisher scores were used to assess aSAH severity. Neurologic outcome was assessed using the Modified Rankin Scale (mRS) at 1-year post-aSAH. Serum was taken at various time points (24, 72, and 168 h, and 14 days). Serum samples from aSAH patients and healthy controls were subjected to reverse transcription (RT) quantitative real-time PCR (RT-qPCR). A poor outcome at 1 year was associated with significantly higher levels of miR-1297 value at the four time points, higher WFNS grade, higher Hunt-Hess grade, and higher Fisher score. Serum miR-1297 levels were significantly higher in patients, compared with healthy controls. There were significant correlations of miR-1297 concentrations in serum with severity in aSAH. The AUCs of miR-1297 at the four time points for distinguishing the aSAH patients from healthy controls were 0.80, 0.94, 0.77, and 0.59, respectively. After multivariate logistic regression analysis, only miR-1297 at 24 and 72 h enabled prediction of neurological outcome at 1 year. Serum was an independent predictive factor of poor outcome at 1 year following aSAH. This result supports the use of miR-1297 in aSAH to aid determination of prognosis.
miRNAs 是翻译的重要调节剂，已被描述为许多心血管疾病的生物标志物，包括中风。本研究的目的是确定动脉瘤性蛛网膜下腔出血 (aSAH) 患者血清 miR-1297 的表达水平，并评估 miR-1297 是否是 aSAH 的预后指标。
我们用血管内介入治疗 128 例 aSAH 患者。世界神经外科学联合会（WFNS）分级、Hunt-Hess 分级和改良 Fisher 评分用于评估 aSAH 严重程度。用改良 Rankin 量表（mRS）在 aSAH 后 1 年评估神经功能结局。在不同时间点（24、72 和 168 h 及 14 天）采集血清。从 aSAH 患者和健康对照者的血清样本进行逆转录（RT）定量实时 PCR（RT-qPCR）。1 年时预后不良与四个时间点 miR-1297 值显著升高、WFNS 分级、Hunt-Hess 分级和 Fisher 评分显著升高相关。与健康对照者相比，患者血清 miR-1297 水平显著升高。血清 miR-1297 浓度与 aSAH 严重程度显著相关。四个时间点 miR-1297 区分 aSAH 患者和健康对照者的 AUC 分别为 0.80、0.94、0.77 和 0.59。多变量 logistic 回归分析后，只有 24 和 72 h 的 miR-1297 可预测 1 年时的神经结局。
血清是 aSAH 后 1 年预后不良的独立预测因素。这一结果支持使用 miR-1297 辅助确定 aSAH 的预后。
